October 8, 2009 — Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique with comparable sensitivity to breast magnetic resonance imaging (MRI) for detecting breast carcinoma when used in pre-surgical planning for patients with known cancer diagnoses and is substantially less expensive than MRI, according to findings presented today at the American Society of Clinical Oncology Breast Cancer Symposium in San Francisco, Calif.

“BSGI proved to be a cost-effective breast diagnostic imaging modality, able to detect mammographically occult breast cancers and provide comparable sensitivity to MRI at a higher patient compliance rate and lower cost,” said Margaret Bertrand, M.D., director of Breast Imaging at Solis Bertrand Breast Center in Greensboro, N.C.

In this study, BSGI was performed prior to needle biopsy on 123 patients with 126 breast carcinomas who subsequently had a post-biopsy, preoperative breast MRI for surgical planning in accordance with the ACS guidelines. BSGI and MRI both detected 123 of the 126 malignancies, yielding a sensitivity of 97 percent for both studies. Eleven percent of the cancers found with BSGI were detected in patients with equivocal or negative mammograms. Four patients with cancer were excluded from the study because they were unable to
undergo breast MRI. The cost for conducting BSGI in this group of patients was $37,321.87 compared to the cost for conducting breast MRI in this group was $122,314.89.

BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as focal areas on the BSGI image.

For more information: www.dilon.com


Related Content

News | Women's Health

June 23, 2025 — Susan G. Komen, the world’s leading breast cancer organization, recently announced it is awarding $10.8 ...

Time June 23, 2025
arrow
Feature | Women's Health | Christine Murray

In breast cancer detection, speed and accuracy are more than clinical goals – they can significantly increase chances ...

Time June 17, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Imaging Software Development

May 27, 2025 — DeepLook Medical, a company advancing medical imaging through visual enhancement technology, recently ...

Time May 28, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
News | Mammography

Sept. 30, 2024 — Siemens Healthineers recently announced the Food and Drug Administration’s premarket approval (PMA) for ...

Time September 30, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
Subscribe Now